Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
- Resource Type
- Article
- Source
- In
The Lancet Oncology April 2017 18(4):464-472 - Subject
Primary Research Articles - Language
- ISSN
- 1470-2045